Introducing Comfora, A New Treatment For Interstitial Cystitis

Pentosan Polysulfate Now Available In India & By Mail Order

Introducing ComforaSwati Spentose Pvt. Ltd (India) has launched the first generic form of Pentosan Polysulfate. Known as COMFORA, it is now available for use throughout India and shortly by mail order globally. COMFORA is India's first affordable and effective treatment for the urological disorder Interstitial Cystitis (IC).

Interstitial Cystitis is a chronic, inflammatory disorder of the urinary bladder and is characterized by variable degrees of bladder pain, urinary frequency and urgency (urinary incontinence). Millions of people, especially women, suffer from this long-term bladder condition which is also known as painful bladder syndrome. As a clinical entity in India, IC is not well defined, poorly understood, inadequately treated and is extraordinarily bothersome to the patient. Awareness about IC in India is still lacking leading to patients sometimes going their whole lives without a correct diagnosis and proper medication.

The key ingredient of COMFORA is the molecule Pentosan Polysulfate sodium which is the first and only FDA-approved oral treatment for IC. It is a capsule taken orally, usually 3 times a day. Information about IC and details of the product were shared by Vishal Jajodia, CEO Swati Spentose Pvt. Ltd. and Dr. Nagendra Mishra, India's leading urologist and expert in the treatment of Interstitial Cystitis.

Swati Spentose is committed to revolutionizing the treatment of this neglected disease and has spent the last 7 years developing COMFORA. All the core research and pre-clinical work has been done at the prestigious Mt. Sinai Hospital in New York thereby giving it unsurpassable scientific validation. SSPL also has on board a number of leading scientists and clinicians from around the globe. SSPL has also built a state of the art manufacturing facility in compliance with the latest guidelines laid down by the US Food & Drug Administration, Japanese Ministry of Health & Welfare and the European Agency for the evaluation of Medicinal Products.

Introducing ComforaVishal Jajodia said "We recognized the need for an effective treatment for Interstitial Cystitis in India and are delighted that after investing in 7 years of dedicated research, the hard work and capabilities of our staff and the global authorities on the subject working with us, has brought us to this stage. We received final approval from the DCGI in May 2010. SSPL is dedicated towards building a strong community platform to reach out and support patients suffering from Interstitial Cystitis, so we will take adequate measure to create awareness about the problem and treatment available among public and doctors."

Dr. Nagendra Mishra, globally and nationally recognized authority on Interstitial Cystitis commented, "Interstitial Cystitis is a disorder that severely affects the day to day living of those suffering from it. It interferes with their sleep, work, social activities, and quality of life. With the introduction of Comfora into the market, my patients and people suffering from IC all over the country will greatly benefit. I extend my whole hearted support to Swati Spentose in their efforts to bring to India a revolutionary treatment for this poorly understood disease."

Dr. Rajeev Sood, HOD at Dr. Ram Manohar Lohia Hospitaland PGIMER, New Delhi, commented "It's a boon for Indian IC patients that pentosan is now made available in India by Swati Spentose Pvt. Ltd. I can now prescribe Comfora to IC patients without any hesitation."

This is a long awaited development for the interstitial cystitis community. Jill Osborne, President of the Interstitial Cystitis Network, offered "In this struggling economy, many patients cannot afford brand name medications. Having a much more affordable form of the same medication is indeed welcome news! We anxiously await its availability in the USA."

COMFORA is currently available for use by patients throughout India. The company anticipates offering Comfora by mail order to patients throughout the world shortly.

For additional information, please visit: